USPTO issues patent for Advaxis’ live Listeria HER2/neu immunotherapy

The U.S. Patent and Trademark Office has issued to Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, patent number 7,784,729 titled "Methods and Compositions for Immunotherapy of Cancer," based upon patent application 10/949,667.

“Our patent strategy involves many interlocking elements”

This patent extends the company's proprietary technology to include fusion proteins using the company's proprietary truncated listeriolysin O (tLLO) in combination with the proprietary HER2/neu fragments previously approved by the USPTO, as either genomically modified or plasmid based Listeria vaccines for the treatment of breast and other cancers. This broadens Advaxis' patent position and extends it in time with additional compositions of matter, uses and methods.

"Our patent strategy involves many interlocking elements," said Advaxis EVP of Science and Operations Dr. John Rothman. "This patent work performed by Dr. Yvonne Paterson and Dr. Reshma Singh, who has recently joined the company, provides an entirely new way of utilizing effective portions of the antigen HER2/neu and is the basis for the vaccine we are currently preparing for clinical trials next year."

Source : Advaxis, Inc